DeLand F H, Kim E E, Simmons G, Goldenberg D M
Cancer Res. 1980 Aug;40(8 Pt 2):3046-9.
External in vivo imaging of tumors with radioactively labeled antibodies to tumor-associated antigens requires processing to remove interfering nontarget radioactivity. Processing entails the use of simulated nontarget compounds labeled with a radionuclide physically different from that on the antibody and substraction of the simulated nontarget activity from the nontargeted antibody. A 2-fold increase of the target to nontarget radioactivity is achieved that has made possible a greater than 70% tumor detection rate.
使用针对肿瘤相关抗原的放射性标记抗体对肿瘤进行体外活体成像需要进行处理以去除干扰性非靶标放射性。处理过程需要使用用与抗体上的放射性核素物理性质不同的放射性核素标记的模拟非靶标化合物,并从非靶向抗体中减去模拟非靶标活性。实现了靶标与非靶标放射性的2倍增加,这使得肿瘤检测率高于70%成为可能。